Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × talimogene laherparepvec × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 8 Gastrointestinal 4 Sarcoma 3 Breast 3 Head & Neck 2 Thoracic 1 Gynecologic 1

Conditions

Peritoneal Neoplasms 1

Interventions

Paclitaxel 130 Carboplatin 113 Bevacizumab 76 Cisplatin 57 pembrolizumab 49 Taxes 41 Gemcitabine 40 liposomal doxorubicin 32 Topotecan 32 olaparib 25 Cyclophosphamide 22 Immunoglobulin G 21 human papillomavirus vaccine, L1 type 16, 18 20 Disulfides 20 Brachytherapy 20 Docetaxel 19 Platinum 18 niraparib 17 1,2-diaminocyclohexaneplatinum II citrate 17 Nivolumab 15 Magnetic Resonance Spectroscopy 15 rucaparib 14 durvalumab 14 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14 Doxorubicin 14 fludarabine phosphate 12 fludarabine 12 Radiotherapy, Intensity-Modulated 12 Radiation 12 Albumin-Bound Paclitaxel 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03663712 2024-11-20

TEMPO

Duke University

Phase 1 Completed

28 enrolled 10 charts

Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡